February 22, 2012—The head of the Health Resources and Services Administration (HRSA) has written an open letter to 340B stakeholders describing actions both underway and in the works at her agency “to eliminate improper payments and reduce the risk of waste, fraud, and abuse” in the drug discount program.
“Two of the most important responsibilities we have are to ensure that our programs are free of fraud, waste, and abuse and that we do everything we can to maximize the positive impact of every dollar we spend,” wrote HRSA Administrator Mary Wakefield in the letter, which was posted on the Office of Pharmacy Affairs (OPA) Web site today.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)